Compliance
Peptide compliance, state by state.
A working reference for practitioners: federal 503A/503B framework, state pharmacy-board posture, and primary-source citations.
Educational reference, not legal advice.
Peptide regulation evolves rapidly at both federal and state levels. Always verify current FDA bulks list status, your state board of pharmacy guidance, and consult qualified counsel before prescribing, compounding, or marketing peptide therapy.
Federal framework
The floor is set by FDA. The ceiling is set by your state.
Peptide therapy in the United States is governed primarily by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. State boards of pharmacy and medical boards layer additional rules on top — including non-resident pharmacy licensure, telehealth registration, and prescriber–patient relationship standards.
Traditional compounding
State-licensed pharmacies and physicians compounding for individually identified patients pursuant to a valid prescription. Limited to substances on the 503A bulks list, USP/NF monographs, or FDA-approved drug components.
Outsourcing facilities
Larger-scale sterile compounders registered with FDA. Governed by interim policy on bulk substances and stricter cGMP-style oversight.
Peptide-by-peptide
Federal status of common peptides.
| Peptide | Federal status | Practitioner note |
|---|---|---|
| BPC-157 | Category 2 (significant safety concerns) | FDA placed BPC-157 in Category 2; 503A pharmacies generally do not compound for human use. |
| Tesamorelin | FDA-approved (Egrifta) — DDI list eligible | Approved indication for HIV-associated lipodystrophy; off-label use governed by clinical context. |
| Sermorelin | Compoundable (state-board dependent) | Historically compounded by 503A pharmacies; verify current state-board guidance. |
| GHK-Cu (injectable) | Category 2 (injectable) | Injectable form raised safety concerns; topical use treated separately. |
| CJC-1295 / Ipamorelin | Removed from Category 1 / not on bulks list | Not currently compoundable through 503A pharmacies under FDA framework. |
| Semaglutide / Tirzepatide | FDA-approved; shortage-list dependent | Compoundable while on FDA shortage list; status updates frequently — verify before prescribing. |
State posture index
Compliance posture by state.
References
Primary sources.
Citations are linked inline in the state table. Always confirm against the most recent version of each source — federal and state guidance updates frequently.
- 1
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
U.S. Food & Drug Administration
Federal framework for what 503A compounding pharmacies may use. Defines the bulks list categorization that drives state board posture.
View source - 2
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2)
U.S. Food & Drug Administration
FDA Category 2 list: substances FDA has identified as raising significant safety concerns (e.g., several peptides moved here in 2023).
View source - 3
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B (Jan 2025)
U.S. Food & Drug Administration / CDER
Outsourcing facility (503B) interim policy for bulk substance use, governing larger-scale sterile compounders.
View source - 4
Statement on the Compounding of Peptide Products (March 2024)
Alliance for Pharmacy Compounding
Industry overview of the federal and state regulatory framework specifically applied to peptide compounding.
View source - 5
Florida Telehealth Out-of-State Practitioner Registration
Florida Department of Health
Required registration for out-of-state prescribers practicing into Florida via telehealth.
View source
Need provider-grade guidance?
PEP.ED certification covers compliance, documentation, and informed-consent best practices.